
Hilo, formerly known as Aktiia, has secured $42 million in an oversubscribed Series B funding round. The investment was co-led by Earlybird Health and Wellington Partners, with new backing from Kfund and naturalX Health Ventures. Existing investors redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures also participated.
The round brings Hilo’s total funding to over $100 million, marking a key moment in the company’s growth as it expands its global presence and prepares for U.S. market entry.
Hilo operates in the rapidly evolving category of cuffless blood pressure monitoring (CBPM), which offers a more seamless and frequent way to track hypertension—a condition affecting billions worldwide. The company has achieved regulatory milestones in Canada, Australia, and Saudi Arabia, along with CE certification for its smartphone-based BP tracking system.
Raghav "Rags" Gupta, CEO of Hilo, stated: “This funding round is a testament to the confidence our investors have in Hilo's groundbreaking technology and our mission to manage the world's blood pressure via more frequent, convenient and accurate measurements.”
With the new capital, Hilo plans to further develop its CBPM platform, pursue enterprise use cases, and expand into new markets. The company is also preparing for FDA submission in the U.S., supported by a recent clinical trial.
In tandem with product innovation, Hilo will scale operations to support broader healthcare partnerships and deepen its machine learning capabilities, positioning the company as a leader in blood pressure intelligence.
Founded in 2018 in Switzerland, Aktiia built a reputation for user-friendly and clinically validated blood pressure monitoring. Now rebranded as Hilo, the company reflects a broader ambition: to make cuffless BP tracking universally accessible.
To date, Hilo has sold more than 120,000 devices and trained its proprietary ML model on billions of optical signals and hundreds of millions of calibration points. The platform is backed by a multidisciplinary team with expertise in biomedical signal processing, over 120 peer-reviewed publications, and 35+ patents.
As part of the Series B round, Christoph Massner of Earlybird Health will join Hilo’s board. He praised Hilo’s ability to bridge medical-grade precision with user-focused accessibility.
“It's a rare combination that empowers users to take meaningful control of their health with minimal effort,” said Massner.
Johannes Fischer of Wellington Partners added: “We believe that real-time and continuous access to blood pressure information will change the way we think about the monitoring and management of one of the most common risk factors to human health.”

